Iscalimab - Novartis
Alternative Names: CFZ-533; NVP-CFZ533; OM11-62-MFLatest Information Update: 10 Sep 2024
At a glance
- Originator Novartis; XOMA
- Developer Novartis
- Class Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Monoclonal antibodies; Urologics
- Mechanism of Action CD40 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Graves' disease; Hidradenitis suppurativa; Liver transplant rejection; Lupus nephritis; Myasthenia gravis; Sjogren's syndrome; Systemic lupus erythematosus; Type 1 diabetes mellitus
- Phase I/II Renal transplant rejection
- No development reported Rheumatoid arthritis
Most Recent Events
- 19 Aug 2024 Novartis completes the phase-II TWINSS Extn trial for Sjögren's Syndrome in Argentina, Italy, Turkey, Greece, Germany, Portugal, France, Netherlands, Sweden, Australia, Austria, Brazil, Canada, Chile, Colombia, Hungary, Israel, Japan, Romania, Russia, South Korea, UK and USA (SC) (NCT04541589)
- 12 Jun 2024 Efficacy and adverse events data from a phase IIb TWINSS trial in Sjogren's syndrome presented at the25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 04 Jun 2024 Novartis Pharmaceuticals completes a phase-II clinical trials in Type 1 diabetes mellitus (In children, In adults, In adolescents) in Belgium, Italy, Slovenia, Spain, United Kingdom (IV) (SC) (NCT04129528) (EudraCT2018-004553-25)